<DOC>
	<DOCNO>NCT01506895</DOCNO>
	<brief_summary>The purpose study characterize systemic ocular safety tolerability , pharmacokinetics , exploratory efficacy pharmacodynamics 3 month repeat administration oral darapladib diabetic macular edema patient centre involvement .</brief_summary>
	<brief_title>A Phase 2 Clinical Study Investigate Effects Darapladib Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description>This multi-national , multi-centre , randomised , double-masked , placebo-controlled , parallel-group study repeat oral administration 160 mg darapladib 3 month adult subject DME centre involvement . Eligible subject randomise 2:1 ratio active treatment placebo , placebo group allow comparison safety treatment arm minimize open label effect observe visual acuity endpoint . The primary aim study determine effect repeat dose darapladib mean change baseline best-corrected visual acuity ( BCVA ) spectral domain OCT ( SD-OCT ) centre subfield . The study eye examine change life study . As investigational treatment systemic , fellow eye may examine tandem provide additional data .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Darapladib</mesh_term>
	<criteria>A female subject eligible participate : Nonchildbearing potential childbearing potential agrees contraception appropriate period time Diagnosis diabetes mellitus ( type 1 type 2 ) Confirmation DME study eye angiography Confirmation retinal thickening study eye study doctor Best correct visual acuity score 7824 letter study eye Additional eye disease study eye could compromise study assessment Intraocular surgery , laser photocoagulation study eye within 3 month dose Uncontrolled intraocular pressure study eye despite treatment glaucoma medication Uncontrolled diabetes Certain type liver disease Severe reduction kidney function OR removal kidney OR kidney transplant Blood pressure high normal despite lifestyle change treatment medication Certain medication may interfere study medication eye assessment ( identify study doctor ) Current severe heart failure Severe asthma poorly control medication Previous severe allergic reaction food , medication , drink , insect sting , etc If birth parent least 50 % Japanese , Chinese , Korean ancestry , must blood sample collected LpPLA2 activity . Those LpPLA2 activity less equal 20.0 nmol/min/mL exclude Recent participation study investigational medication Any reason investigator deems subject participate study Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
</DOC>